Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3079 Novel Symptoms and Therapy of Multiple Endocrine Neoplasia Type 1

Introduction: MEN1 is a rare autosomal inherited disease with hallmark of hyperparathyroidism, duodenopancreatic NENs and pituitary tumor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: bai J

Authors: Bai J, Tang Q,

Keywords: MEN1, LGCS, NENs, gastrinoma, Parathyroid carcinoma,

#2984 AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Serve as a Target for Molecular Imaging and Therapy

Introduction: Peptide receptor targeting has proven to be a pivotal tool for diagnostic imaging and radioligand therapy of neuroendocrine neoplasms (NENs), which frequently express somatostatin receptors (SSTRs) on their cell surface. However, up to 30 % of NEN patients do not benefit from SSTR-based approaches, others develop a resistance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Grötzinger C, Exner S, Schuldt C, Du J, Sachindra S,

Keywords: receptor, targeting, imaging, prrt, peptide, angiotensin,

#2949 Sunitinib May Be an Effective Treatment for Hypercalcemia Due To a Metastatic Pancreatic Neuroendocrine Tumor

Introduction: Malignant hypercalcemia due to neuroendocrine tumor(NET) is rare, and only a few reports are available in the literature.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Wang C

Authors: Wang C, Qi Z, Tan H, Tan H,

Keywords: hypercalcemia, pancreatic NET, sunitinib,

#2819 Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue

Introduction: Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rinzivillo M

Authors: De Felice I, Rinzivillo M, Pratesi M, Magi L, Annibale B,

Keywords: Pancreatic Exocrine Insufficiency,

#2761 Diagnosis and Management of Insulinomas. The Use of Current Practices in Pakistan

Introduction: Insulinomas are rare functional and benign neuroendocrine tumors of Pancreas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Fatima A

Authors: Fatima A, Zaidi S,

Keywords: Insulinoma, progression-free survival, sunitinib, malignant,